MCID: NSP012
MIFTS: 67

Nasopharyngeal Carcinoma

Categories: Rare diseases, Cancer diseases, Respiratory diseases, Gastrointestinal diseases, Genetic diseases

Aliases & Classifications for Nasopharyngeal Carcinoma

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 57 12 76 53 59 29 55 6 40 73
Nasopharyngeal Cancer 57 53 37
Malignant Neoplasm of Nasopharynx 12 73
Nasopharyngeal Carcinoma 1 57 13
Nasopharyngeal Neoplasms 44 73
Nasopharynx Carcinoma 12 15
Malignant Neoplasm of Other Specified Sites of Nasopharynx 12
Primary Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Posterior Wall of Nasopharynx 12
Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Superior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx 12
Malignant Tumor of Posterior Wall of Nasopharynx 12
Malignant Tumor of Anterior Wall of Nasopharynx 12
Malignant Tumor of Lateral Wall of Nasopharynx 12
Squamous Cell Carcinoma of the Nasopharynx 59
Malignant Neoplasm of Nasopharyngeal Wall 12
Malignant Neoplasm of Roof of Nasopharynx 12
Malignant Nasopharyngeal Tumor 12
Carcinoma of Nasopharynx 12
Cancer of Nasopharynx 73
Nasopharynx Cancer 12
Npca 57
Npc 57

Characteristics:

Orphanet epidemiological data:

59
nasopharyngeal carcinoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

HPO:

32
nasopharyngeal carcinoma:
Inheritance polygenic inheritance


Classifications:

Orphanet: 59  
Rare respiratory diseases


External Ids:

OMIM 57 607107
Disease Ontology 12 DOID:9261
MeSH 44 D009303
NCIt 50 C9321
Orphanet 59 ORPHA150
UMLS via Orphanet 74 C0238301 C2931822 C0153392
MESH via Orphanet 45 C538339
ICD10 via Orphanet 34 C11.0 C11.1 C11.2 more
MedGen 42 C2931822
KEGG 37 H00054
SNOMED-CT via HPO 69 126680004

Summaries for Nasopharyngeal Carcinoma

OMIM : 57 Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107)

MalaCards based summary : Nasopharyngeal Carcinoma, also known as nasopharyngeal cancer, is related to sarcoma and adenocarcinoma, and has symptoms including headache, tinnitus and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Cisplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include the nasopharynx, lung and lymph node, and related phenotype is neoplasia of the nasopharynx.

Disease Ontology : 12 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or \

Wikipedia : 76 Nasopharynx cancer or nasopharyngeal carcinoma (NPC) is the most common cancer originating in the... more...

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2 Nasopharyngeal Carcinoma 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 222)
# Related Disease Score Top Affiliating Genes
1 sarcoma 31.5 HOTAIR HRAS PIK3CA TP53
2 adenocarcinoma 31.4 H19 HRAS PIK3CA TP53
3 squamous cell carcinoma 31.3 CDKN2B-AS1 FOXCUT H19 HOTAIR HRAS MALAT1
4 tongue squamous cell carcinoma 31.2 AFAP1-AS1 MALAT1 TP53
5 b-cell lymphomas 31.0 GAS5 HOTAIR MALAT1 TP53
6 leukemia 30.9 CDKN2B-AS1 GAS5 HOTAIR NEAT1 NRAS TP53
7 squamous cell carcinoma, head and neck 30.9 GAS5 H19 HOTAIR HRAS MIR29C PIK3CA
8 renal cell carcinoma, nonpapillary 30.8 GAS5 H19 HOTAIR MALAT1 NPTN-IT1
9 glioma 30.6 CDKN2B-AS1 GAS5 H19 HOTAIR MALAT1 NEAT1
10 esophageal cancer 30.5 CDKN2B-AS1 FOXD2-AS1 GAS5 H19 HOTAIR HRAS
11 breast cancer 30.1 CDKN2B-AS1 FOXCUT GAS5 H19 HOTAIR HRAS
12 lung cancer 29.3 AFAP1-AS1 CDKN2B-AS1 FOXD2-AS1 GAS5 H19 HOTAIR
13 nasopharyngeal carcinoma 3 12.4
14 nasopharyngeal carcinoma 2 12.3
15 nasopharyngeal cancer, childhood 12.0
16 niemann-pick disease, type c1 11.9
17 prostate squamous cell carcinoma 11.4 HRAS PIK3CA TP53
18 esophagus adenocarcinoma 11.4 AFAP1-AS1 PIK3CA TP53
19 lymphoepithelioma-like carcinoma 11.4
20 skin squamous cell carcinoma 11.4 HRAS PIK3CA TP53
21 rare adenocarcinoma of the breast 11.4 PIK3CA TP53
22 ovarian cancer 1 11.4 HRAS PIK3CA TP53
23 malignant ovarian surface epithelial-stromal neoplasm 11.4 HRAS PIK3CA TP53
24 ovary epithelial cancer 11.4 HRAS PIK3CA TP53
25 serous cystadenocarcinoma 11.4 HRAS PIK3CA TP53
26 adult hepatocellular carcinoma 11.4 PIK3CA TP53
27 cystadenocarcinoma 11.4 HRAS PIK3CA TP53
28 respiratory system cancer 11.4 HRAS MALAT1 PIK3CA TP53
29 suppression of tumorigenicity 12 11.3 HRAS PIK3CA TP53
30 female reproductive organ cancer 11.3 HRAS PIK3CA TP53
31 malignant spiradenoma 11.3 PIK3CA TP53
32 nasopharyngitis 11.3
33 apocrine adenoma 11.3 HRAS PIK3CA
34 uterine carcinosarcoma 11.3 HRAS PIK3CA TP53
35 prostate adenoid cystic carcinoma 11.3 HRAS PIK3CA
36 lung squamous cell carcinoma 11.2 HRAS NPTN-IT1 PIK3CA TP53
37 meningeal melanomatosis 11.2 HRAS NRAS TP53
38 spitz nevus 11.2 HRAS TP53
39 pilocytic astrocytoma 11.2 HRAS PIK3CA TP53
40 small cell cancer of the lung 11.2 HOTAIR MALAT1 PIK3CA TP53
41 marek disease 11.2 H19 TP53
42 ovarian serous cystadenocarcinoma 11.2 HRAS NRAS PIK3CA TP53
43 liver angiosarcoma 11.2 HRAS NRAS TP53
44 renal cell carcinoma, papillary, 1 11.2 HRAS NRAS PIK3CA TP53
45 triple-receptor negative breast cancer 11.2 HOTAIR MALAT1
46 giant congenital nevus 11.2 HRAS NRAS
47 nevus, epidermal 11.2 HRAS NRAS PIK3CA
48 acneiform dermatitis 11.2 HRAS NRAS PIK3CA
49 skin melanoma 11.2 HRAS NRAS PIK3CA TP53
50 integumentary system cancer 11.2 HRAS NRAS TP53

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Clinical features from OMIM:

607107

Human phenotypes related to Nasopharyngeal Carcinoma:

32
# Description HPO Frequency HPO Source Accession
1 neoplasia of the nasopharynx 32 HP:0100630

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache, tinnitus, rhinorrhea

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
3
Bupropion Approved Phase 4,Phase 2,Early Phase 1 34841-39-9, 34911-55-2 444
4
Dopamine Approved Phase 4,Phase 2,Early Phase 1 51-61-6, 62-31-7 681
5
Nicotine Approved Phase 4,Not Applicable,Early Phase 1 54-11-5 942 89594
6 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
8 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Antidepressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
14 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Early Phase 1
15 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Early Phase 1
16 Dopamine Agents Phase 4,Phase 2,Early Phase 1
17 Dopamine Uptake Inhibitors Phase 4,Phase 2,Early Phase 1
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Early Phase 1
19 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable,Early Phase 1
20 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
21 Nicotinic Agonists Phase 4,Not Applicable,Early Phase 1
22
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
23
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
24
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
25
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
26
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
27
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
28
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
29
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
30
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
31
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
32
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
33
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
34
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
35
Cetuximab Approved Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
36
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
37
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
39
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
40
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
41
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
42
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
43
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
44
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
45
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
46
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
47
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
48
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
49
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
50
Aprepitant Approved, Investigational Phase 3,Phase 2 170729-80-3 151165 6918365

Interventional clinical trials:

(show top 50) (show all 554)
# Name Status NCT ID Phase Drugs
1 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
2 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
3 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
5 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
6 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02948699 Phase 4
7 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury Recruiting NCT03069820 Phase 4 docetaxel and cisplatin
8 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
9 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Unknown status NCT01817023 Phase 3 Cisplatin
10 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
11 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
12 Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
13 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
14 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
15 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
16 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
17 Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
18 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
19 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
20 Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC). Unknown status NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
21 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCIN Unknown status NCT00180973 Phase 3 Hydroxyurea
22 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
23 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
24 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
25 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
26 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
27 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
28 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
29 Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
30 A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma Completed NCT00201396 Phase 3 Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
31 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Completed NCT00274937 Phase 3 amifostine trihydrate;fluorouracil;cisplatin
32 Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
33 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
34 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
35 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
36 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
37 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
38 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
39 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
40 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
41 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
42 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
43 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
44 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
45 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
46 Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma Recruiting NCT03321539 Phase 3 CCRT+GP;CCRT+PF
47 TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma Recruiting NCT03306121 Phase 3 TPF+CCRT;CCRT+ PF
48 TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma Recruiting NCT02940925 Phase 3
49 Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT02958111 Phase 3 Capecitabine
50 Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02460419 Phase 3 capecitabine

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

# Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 29 TP53

Anatomical Context for Nasopharyngeal Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Nasopharyngeal Carcinoma:

19
The Nasopharynx

MalaCards organs/tissues related to Nasopharyngeal Carcinoma:

41
Lung, Lymph Node, Liver, Skin, Brain, Endothelial, T Cells

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 2370)
# Title Authors Year
1
Dosimetric Comparisons of Volumetric Modulated Arc Therapy and Tomotherapy for Early T-Stage Nasopharyngeal Carcinoma. ( 29967769 )
2018
2
A study on the value of narrow-band imaging (NBI) for the general investigation of a high-risk population of nasopharyngeal carcinoma (NPC). ( 29973209 )
2018
3
A Case of Neurotrophic Keratopathy Associated with Nasopharyngeal Carcinoma. ( 29643792 )
2018
4
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. ( 29266526 )
2018
5
Long non-coding RNA n326322 promotes the proliferation and invasion in nasopharyngeal carcinoma. ( 29416735 )
2018
6
Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway. ( 29248577 )
2018
7
Reduced QSOX1 enhances radioresistance in nasopharyngeal carcinoma. ( 29423042 )
2018
8
Lack of association between the distribution of ABO blood groups and nasopharyngeal carcinoma in a population of Southern China. ( 29970653 )
2018
9
miR-93 enhances cell proliferation by directly targeting CDKN1A in nasopharyngeal carcinoma. ( 29434867 )
2018
10
Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma. ( 29971780 )
2018
11
High COX-2 expression contributes to a poor prognosis through the inhibition of chemotherapy-induced senescence in nasopharyngeal carcinoma. ( 29956730 )
2018
12
Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. ( 29451951 )
2018
13
Downregulation of ribophorin II suppresses tumor growth, migration, and invasion of nasopharyngeal carcinoma. ( 29942140 )
2018
14
Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. ( 29428165 )
2018
15
A regulatory mutant on TRIM26 conferring the risk of nasopharyngeal carcinoma by inducing low immune response. ( 29956500 )
2018
16
Promoter hypermethylation of SLIT2 is a risk factor and potential diagnostic biomarker for nasopharyngeal carcinoma. ( 29107007 )
2018
17
LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness. ( 29959065 )
2018
18
Endoscopic Surgery for Delayed Sinonasal Complications of Radiation Therapy for Nasopharyngeal Carcinoma: A Subjective Outcome. ( 29439883 )
2018
19
LncRNA-LINC00460 facilitates nasopharyngeal carcinoma tumorigenesis through sponging miR-149-5p to up-regulate IL6. ( 28987345 )
2018
20
Stable knockdown of ZBTB7A promotes cell proliferation and progression in nasopharyngeal carcinoma. ( 29699474 )
2018
21
Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. ( 29431618 )
2018
22
Using the nasoseptal flap for reconstruction after endoscopic debridement of radionecrosis in nasopharyngeal carcinoma. ( 29336293 )
2018
23
Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. ( 29413277 )
2018
24
Retraction Note to: Differences in the expression profiles of claudin proteins in human nasopharyngeal carcinoma compared with non-neoplastic mucosa. ( 29940962 )
2018
25
MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition. ( 29427737 )
2018
26
Activation of SREBP1-mediated lipogenesis by the Epstein-Barr Virus-encoded LMP1 promotes cell proliferation and progression of nasopharyngeal carcinoma. ( 29968360 )
2018
27
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. ( 28857155 )
2018
28
Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy. ( 29439312 )
2018
29
Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution. ( 29046165 )
2018
30
Elevated antibodies against Epstein-Barr virus among individuals predicted to carry nasopharyngeal carcinoma susceptibility variants. ( 29975184 )
2018
31
Diffusion kurtosis imaging of a human nasopharyngeal carcinoma xenograft model: Initial experience with pathological correlation. ( 29221965 )
2018
32
The diagnosis and management of rare cystic liver metastases from nasopharyngeal carcinoma: A case report. ( 29952994 )
2018
33
Vimentin is a crucial target for anti-metastasis therapy of nasopharyngeal carcinoma. ( 28744809 )
2018
34
Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma. ( 29425953 )
2018
35
Functions and Roles of Long-Non-Coding RNAs in Human Nasopharyngeal Carcinoma. ( 29448252 )
2018
36
=Osteoradionecrosis of the Skull Base in Nasopharyngeal Carcinoma: Incidence and Risk Factors. ( 29960057 )
2018
37
Calycosin inhibits nasopharyngeal carcinoma cells by influencing EWSAT1 expression to regulate the TRAF6-related pathways. ( 29966979 )
2018
38
BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM. ( 29123267 )
2018
39
Functionalized Graphene Oxide as a nanocarrier of new Copper (II) complexes for targeted therapy on nasopharyngeal carcinoma. ( 29981404 )
2018
40
Association of the rs1760944 polymorphism in the APEX1 base excision repair gene with risk of nasopharyngeal carcinoma in a population from an endemic area in South China. ( 28464393 )
2018
41
Early evaluation of radiation-induced parotid damage in patients with nasopharyngeal carcinoma by T2 mapping and mDIXON Quant imaging: initial findings. ( 29422068 )
2018
42
Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma. ( 29973197 )
2018
43
Correction to: Retrospective dosimetry study of intensity-modulated radiation therapy for nasopharyngeal carcinoma: measurement-guided dose reconstruction and analysis. ( 29941041 )
2018
44
Clinical Variables for Prediction of the Therapeutic Effects of Bevacizumab Monotherapy in Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis. ( 29413276 )
2018
45
The value of radical radiotherapy in the primary tumor of newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients. ( 29943267 )
2018
46
Baicalin hydrate inhibits cancer progression in nasopharyngeal carcinoma by affecting genome instability and splicing. ( 29416665 )
2018
47
Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma. ( 29977542 )
2018
48
Long non-coding RNA PVT1 predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma. ( 29445147 )
2018
49
Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update. ( 29413761 )
2018
50
The detection and significance of T cells in nasopharyngeal carcinoma patients. ( 29970685 )
2018

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

6
(show top 50) (show all 56)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
2 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
3 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
4 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
5 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
6 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
7 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
8 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
9 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
10 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
11 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
12 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
13 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
14 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
15 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
16 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
17 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
18 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
19 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913254 GRCh38 Chromosome 1, 114713909: 114713909
20 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913254 NCBI36 Chromosome 1, 115058053: 115058053
21 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
22 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
23 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
24 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
25 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
26 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
27 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
28 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
29 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
30 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
31 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
32 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
33 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
34 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 GRCh38 Chromosome 1, 114713907: 114713907
35 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh37 Chromosome 10, 123258036: 123258036
36 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh38 Chromosome 10, 121498522: 121498522
37 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
38 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
39 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
40 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
41 FGFR2 NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh37 Chromosome 10, 123258034: 123258034
42 FGFR2 NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh38 Chromosome 10, 121498520: 121498520
43 FGFR2 NM_022970.3(FGFR2): c.1917T> A (p.Asn639Lys) single nucleotide variant Likely pathogenic rs1057519854 GRCh37 Chromosome 10, 123247577: 123247577
44 FGFR2 NM_022970.3(FGFR2): c.1917T> A (p.Asn639Lys) single nucleotide variant Likely pathogenic rs1057519854 GRCh38 Chromosome 10, 121488063: 121488063
45 FGFR2 NM_000141.4(FGFR2): c.1642A> C (p.Ile548Leu) single nucleotide variant Likely pathogenic rs1057519901 GRCh37 Chromosome 10, 123258039: 123258039
46 FGFR2 NM_000141.4(FGFR2): c.1642A> C (p.Ile548Leu) single nucleotide variant Likely pathogenic rs1057519901 GRCh38 Chromosome 10, 121498525: 121498525
47 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
48 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
49 TP53 NM_001126114.2(TP53): c.638G> T (p.Arg213Leu) single nucleotide variant Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
50 TP53 NM_001126114.2(TP53): c.638G> T (p.Arg213Leu) single nucleotide variant Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893

Cosmic variations for Nasopharyngeal Carcinoma:

9
(show top 50) (show all 1588)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM2255920 ZNF609 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1984G>A p.A662T 15:64674838-64674838 18
2 COSM6948029 ZFHX3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.8780G>T p.S2927I 16:72793902-72793902 18
3 COSM6973489 ZFHX3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.9572G>A p.G3191D 16:72788704-72788704 18
4 COSM4995216 ZC3H13 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.44C>G p.T15S 13:46045464-46045464 18
5 COSM4995307 ZBTB17 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.281C>T p.A94V 1:15947048-15947048 18
6 COSM6924419 YAP1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1178C>A p.A393D 11:102229765-102229765 18
7 COSM4995092 VPS33A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.221C>A p.A74D 12:122263647-122263647 18
8 COSM4996600 VNN2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.83C>A p.A28D 6:132757801-132757801 18
9 COSM4995249 VANGL1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.884T>C p.L295P 1:115682435-115682435 18
10 COSM4996245 USP34 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.5131C>T p.Q1711* 2:61281110-61281110 18
11 COSM4997193 USP19 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3636G>T p.L1212F 3:49110728-49110728 18
12 COSM4995369 USH2A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.89T>C p.L30S 1:216422248-216422248 18
13 COSM2978223 USH1G upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.520G>A p.D174N 17:74920316-74920316 18
14 COSM4995852 USE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.370G>T p.E124* 19:17216307-17216307 18
15 COSM4996719 TTBK1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1757G>A p.R586Q 6:43263121-43263121 18
16 COSM4997149 TSR2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.187G>C p.D63H 23:54443414-54443414 18
17 COSM1524842 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1783G>A p.D595N 19:31277461-31277461 18
18 COSM4995873 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1121C>T p.P374L 19:31278123-31278123 18
19 COSM6956334 TSC2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1753C>T p.R585C 16:2070492-2070492 18
20 COSM6908589 TSC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.973C>T p.Q325* 9:132911509-132911509 18
21 COSM6973473 TSC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2190G>T p.E730D 9:132903669-132903669 18
22 COSM4995721 TRAF4 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.955C>G p.R319G 17:28749119-28749119 18
23 COSM6973476 TRAF2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.4G>A p.A2T 9:136898744-136898744 18
24 COSM6807199 TRAF2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1177C>T p.R393C 9:136923890-136923890 18
25 COSM2123037 TPR upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3879G>A p.M1293I 1:186341261-186341261 18
26 COSM4996315 TP63 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1413C>G p.S471R 3:189886457-189886457 18
27 COSM10660 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.818G>A p.R273H 17:7673802-7673802 18
28 COSM10808 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.488A>G p.Y163C 17:7675124-7675124 18
29 COSM11376 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.737T>G p.M246R 17:7674226-7674226 18
30 COSM43708 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.422G>A p.C141Y 17:7675190-7675190 18
31 COSM45026 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.560-2A>T p.? 17:7674973-7674973 18
32 COSM44140 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.596G>T p.G199V 17:7674935-7674935 18
33 COSM43555 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.736A>G p.M246V 17:7674227-7674227 18
34 COSM10654 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.637C>T p.R213* 17:7674894-7674894 18
35 COSM10648 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.524G>A p.R175H 17:7675088-7675088 18
36 COSM11073 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1024C>T p.R342* 17:7670685-7670685 18
37 COSM10724 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.839G>C p.R280T 17:7673781-7673781 18
38 COSM11181 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.764T>C p.I255T 17:7674199-7674199 18
39 COSM43906 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.843C>A p.D281E 17:7673777-7673777 18
40 COSM43919 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.856G>T p.E286* 17:7673764-7673764 18
41 COSM43681 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.647T>G p.V216G 17:7674884-7674884 18
42 COSM45643 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.989T>G p.L330R 17:7673539-7673539 18
43 COSM11462 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.388C>G p.L130V 17:7675224-7675224 18
44 COSM10719 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.811G>A p.E271K 17:7673809-7673809 18
45 COSM43559 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.517G>T p.V173L 17:7675095-7675095 18
46 COSM33648 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.559+1G>C p.? 17:7675052-7675052 18
47 COSM11411 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1010G>T p.R337L 17:7670699-7670699 18
48 COSM10770 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1045G>T p.E349* 17:7670664-7670664 18
49 COSM1739496 TNKS upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.583G>A p.V195M 8:9556522-9556522 18
50 COSM4996454 TMPRSS11E upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.268G>T p.A90S 4:68468888-68468888 18

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

7 (show all 41)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270-1 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270-2 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification EVI1 Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MDS1 Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion LMP1 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion LMP2 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication LOC100132832 Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication LOC100133091 Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2L11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Pathways for Nasopharyngeal Carcinoma

Pathways related to Nasopharyngeal Carcinoma according to KEGG:

37
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 HRAS NFKBIA NRAS PIK3CA TP53
2 12.78 HRAS NFKBIA NRAS PIK3CA TP53
3
Show member pathways
12.75 HRAS NFKBIA NRAS PIK3CA TP53
4
Show member pathways
12.66 HRAS NFKBIA NRAS PIK3CA TP53
5
Show member pathways
12.63 HRAS NFKBIA NRAS PIK3CA TP53
6
Show member pathways
12.51 HRAS NFKBIA NRAS PIK3CA TP53
7
Show member pathways
12.46 HRAS NRAS PIK3CA TP53
8
Show member pathways
12.45 HRAS NFKBIA NRAS PIK3CA
9
Show member pathways
12.45 HRAS NFKBIA NRAS PIK3CA TP53
10
Show member pathways
12.44 HRAS NRAS PIK3CA TP53
11
Show member pathways
12.41 HRAS NFKBIA NRAS PIK3CA
12
Show member pathways
12.41 HRAS NFKBIA NRAS PIK3CA TP53
13
Show member pathways
12.38 HRAS NFKBIA NRAS PIK3CA
14
Show member pathways
12.37 HRAS NFKBIA NRAS PIK3CA
15
Show member pathways
12.32 HRAS NFKBIA NRAS PIK3CA
16
Show member pathways
12.26 HRAS NFKBIA NRAS PIK3CA
17 12.22 HRAS NRAS PIK3CA TP53
18
Show member pathways
12.19 HRAS NFKBIA NRAS PIK3CA TP53
19
Show member pathways
12.14 HRAS NFKBIA NRAS PIK3CA
20 12.13 HRAS NFKBIA NRAS PIK3CA TP53
21
Show member pathways
12.1 HRAS NRAS PIK3CA TP53
22
Show member pathways
12.1 HRAS NFKBIA NRAS TP53
23 12.09 HRAS NRAS PIK3CA TP53
24 12.09 HRAS NRAS PIK3CA TP53
25
Show member pathways
12.05 HRAS NFKBIA NRAS PIK3CA
26
Show member pathways
12.04 HRAS NRAS PIK3CA TP53
27 11.96 HRAS NFKBIA NRAS PIK3CA TP53
28 11.93 HRAS NRAS TP53
29
Show member pathways
11.91 HRAS NRAS PIK3CA
30
Show member pathways
11.91 HRAS NFKBIA PIK3CA TP53
31 11.91 HRAS MIR100 MIR29C NRAS PIK3CA TP53
32
Show member pathways
11.88 HRAS NFKBIA NRAS PIK3CA
33 11.86 HRAS NRAS PIK3CA
34 11.85 HRAS NRAS PIK3CA TP53
35 11.82 NFKBIA PIK3CA TP53
36
Show member pathways
11.82 HRAS NRAS PIK3CA
37 11.82 HRAS NRAS PIK3CA TP53
38
Show member pathways
11.8 HRAS NRAS PIK3CA
39 11.79 HRAS NRAS PIK3CA TP53
40
Show member pathways
11.75 HRAS NRAS PIK3CA
41 11.68 HRAS NRAS TP53
42 11.62 HRAS PIK3CA TP53
43 11.61 HRAS NRAS TP53
44 11.28 HRAS NRAS TP53
45 11.27 HRAS NRAS PIK3CA TP53
46 11.14 HRAS NFKBIA NRAS PIK3CA TP53
47 11.06 HRAS NRAS PIK3CA
48 10.96 HRAS PIK3CA
49 10.83 NFKBIA PIK3CA
50 10.79 HRAS NRAS

GO Terms for Nasopharyngeal Carcinoma

Biological processes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.43 HRAS NRAS TP53
2 epidermal growth factor receptor signaling pathway GO:0007173 9.33 HRAS NRAS PIK3CA
3 Fc-epsilon receptor signaling pathway GO:0038095 9.26 HRAS NFKBIA NRAS PIK3CA
4 ERBB2 signaling pathway GO:0038128 8.8 HRAS NRAS PIK3CA

Sources for Nasopharyngeal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....